Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Cigna $1.5 billion senior notes offering
The senior notes are due 2026 and 2033
Revolution Medicines $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Ardelyx $150 million at-the-market offering
The shares are listed on the Nasdaq Global Market
European Biotech Acquisition $220 million combination with Oculis
We advised European Biotech Acquisition on its de-SPAC transaction
Eli Lilly $4 billion notes offering
The investment-grade notes are due 2026, 2033, 2053 and 2063
CStone Pharmaceuticals HK$392.9 million placing of new shares
We advised CStone Pharmaceuticals on the placement
CureVac $250 million follow-on offering
We advised CureVac on the equity offering
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2026, 2033 and 2053
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares